ALIM - Alimera Announces Multiple Presentations Highlighting ILUVIEN® and YUTIQ® Data at Retina Society Annual Congress | Benzinga
ATLANTA, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that clinical data for ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg and YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg will be featured in five presentations during the Retina Society's 56th Annual Scientific Meeting being held in New York City from October 11-14, 2023.
Presentations:
Pouya Dayani, MD "CALM: 24-Month Efficacy and Safety Outcomes From a Phase 4 Registry Study for Patients with Chronic Non-Infectious Posterior Segment Uveitis Treated with a 0.18 mg Fluocinolone Acetonide Intravitreal Insert"
(Wednesday October 11, 4:17 p.m.)
Mathew MacCumber, MD, PhD "Fluocinolone Acetonide (FAc) 0.19mg Implant Improves Vision and Treatment Burden in Patients with Diabetic Macular Edema: The PALADIN Study"
(Friday October 13, 2:30 p.m.)
Seenu Hariprasad, MD "0.19 mg Fluocinolone Acetonide (FAc) Implant Leads to Superior Visual-, Anatomical-, and Treatment Burden-Related Outcomes in Eyes with Better Baseline Visual Acuity (?20/40)"
(Friday October 13, 2:34 p.m.)
Fernando Arevalo, MD "Long-Term Outcomes in Eyes Requiring IOP Lowering Surgery After Treatment with the 0.19 Fluocinolone Acetonide Implant for DME: The PALADIN Study"
(Friday October 13, 2:40 ...